CClinicalTrials.gg
WithdrawnNCT03787082Updated Jul 7, 2022

Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension

A Phase 1 interventional study of Nitrates and Chlorhexidine Gluconate Mouthwash in Pulmonary Hypertension, Heart Failure With Normal Ejection Fraction and Pulmonary Heart Disease and Diseases of Pulmonary Circulation, sponsored by Gladwin, Mark, MD. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-07.

Sponsored by Gladwin, Mark, MD · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Study was never able to start after the pandemic restrictions lifted
Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in volunteers with PH in the breakdown of oral nitrate and effect on hemodynamics.

Read the detailed description

This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in volunteers with PH in the breakdown of oral nitrate and effect on hemodynamics.

The investigators will enroll 40 PH patients over three years. 5 healthy participants will be enrolled as controls. Participants will receive a single dose of the study drug,:14N Sodium Nitrate(1000mg): standard sodium nitrate, and all will receive one dose of CLA 3g. CLA will be obtained from GNC (General Nutrition Corporation) and given once. Participants will be randomized to receive chlorhexidine gluconate 0.12% (15mL) or placebo to rinse their mouth with for 1 minute.

Oral samples will be collected pre- and post-chlorhexidine treatments and stool samples will be collected post-chlorhexidine treatment.

Right heart catheterization will be performed for clinical or research purposes.

The RHC done (in the last 5 years) that establishes inclusion is not the same RHC done as part of the study in most cases. If there is a strong suspicion of PH based on echocardiography in a patient who has not had a clinical RHC, the first hemodynamic measurements obtained in the clinical RHC will establish inclusion and the RHC study procedures will be performed following confirmation of inclusion.

Participants for whom the RHC done in the study is considered a clinical RHC will be participants who do have an additional follow up RHC scheduled.

Participants for whom the RHC done in the study is considered a research RHC will be those who do not have an additional follow RHC scheduled or who are considered healthy and have not had an RHC before.

Catheterization will generally be performed via the right internal jugular vein access with the assistance of fluoroscopy, if needed. Once the pulmonary arterial (PA) catheter has been placed in proper position, measured values will be obtained. The investigators often perform simultaneous measurement of right atrial pressure and distal pressure (PAP/PAWP) using two transducers in order to assess both pressures during vasodilator challenge, or other confrontational testing. An initial hemodynamic profile will be obtained.

With the right heart catheter still in place, participants will be randomized to either chlorhexidine mouthwash or placebo, then after 30 minutes, all will receive 14N oral nitrate and CLA. A repeat hemodynamic profile will be performed after two hours. Nitrate metabolites in plasma will be measured at time 0, 2, and 6 hrs after 14N nitrate dose. Urine nitrite and nitrate will be measured at 0 and 6 hours. Participants will be monitored with continuous pulse oximetry and EKG monitoring. Blood pressure measurements will be performed every 15 minutes during the catheterization. Pressure-volume loop and impedance analysis will be performed at the time of the right heart catheterization (RHC) using the micromanometer catheter technique to simultaneously measure RV pressure and pulmonary blood flow.

02

Conditions studied

  • Pulmonary Hypertension
  • Heart Failure With Normal Ejection Fraction
  • Pulmonary Heart Disease and Diseases of Pulmonary Circulation
03

In context

Hypertension, Pulmonary

1,105 studies on the registry are indexed under Hypertension, Pulmonary; 234 are open to participants now.

Browse Hypertension, Pulmonary studies →

Lead sponsor

Gladwin, Mark, MD is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or female, 18 years of age or older
  • Undergoing clinical right heart catheterization or had a RHC in past 5 years if in PH group
  • Pulmonary Hypertension: hemodynamically defined by a mean PAP ≥ 25 mm Hg and have a PVR > 3 Woods units and normal cardiac index (>2.0 L/min/m2)
  • Healthy Control group: no history of or active cardiac or pulmonary disease
  • Ability to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Use of systemic antibiotics and/or chlorhexidine mouthwash within the previous three months
  • Use of immune suppression (chemotherapy, oral prednisone greater than 20mg per day, etc) with in the previous three months
  • Use of phosphodiesterase-5 inhibitors (tadalafil, sildenafil, etc) within 7 days before study drug administration
  • Current pregnancy or lactation
  • Uncontrolled systemic hypertension based on repeated measurement of sitting systolic blood pressure >185 mm Hg or sitting diastolic blood pressure >110 mm Hg
  • Has chronic renal insufficiency as defined by serum creatinine >3 mg/dL in the last 6 months or requiring dialytic support as reported in the medical record
  • Known history of left ventricular ejection fraction \< 40% by multiple gated acquisition scan (MUGA), angiography, or echocardiography
  • History of atrial septostomy
  • Repaired or unrepaired congenital heart disease
  • Pericardial constriction
  • Restrictive or constrictive cardiomyopathy
  • Symptomatic coronary disease with demonstrable ischemia
  • Addition or change in dosing of hormonal contraception medications (OCP, IUD, Depo-Provera) in the past 4 weeks.
  • Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study or would prevent completion of the study
  • Active participation in other research studies with investigational drugs
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Chlorhexidine Gluconate Mouthwash

    rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral

    Drug: Nitrates · Drug: Chlorhexidine Gluconate Mouthwash

  • Placebo comparator
    Placebo Mouthwash

    rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral

    Drug: Nitrates · Drug: Placebo Mouthwash

Interventions

  • DrugNitrates

    1,000 mg/11.18 mmol, oral

    Also known as: 14N Sodium Nitrate

  • DrugChlorhexidine Gluconate Mouthwash

    chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute

    Also known as: Chlorhexidine mouthwash

  • DrugPlacebo Mouthwash

    sterile water (15mL) mouth rinse for 1 minute

    Also known as: Sterile Water

06

What researchers measure

Primary outcomes

  1. Change in Plasma Nitrate

    Time frame: At baseline and 2 hours post drug administration

  2. Change in Urine Nitrate

    Time frame: At baseline and 2 hours post drug administration

  3. Change in Plasma Nitrate

    Time frame: At baseline and 6 hours post drug administration

  4. Change in Urine Nitrate

    Time frame: At baseline and 6 hours post drug administration

  5. Change in Plasma Nitrate

    Time frame: At 2 hours post drug administration and 6 hours post drug administration

  6. Change in Urine Nitrate

    Time frame: At 2 hours post drug administration and 6 hours post drug administration

Secondary outcomes

  1. Change in Pulmonary Vascular Resistance (PVR)

    Time frame: At baseline and 2 hours post drug administration

07

Study locations

1 site
  • Cathy Kessinger
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Individual participant data

Plan to share: Yes — After de-identification, all participant data collected during the trial will be made available.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03787082
Lead sponsor
Gladwin, Mark, MD
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), University of Pittsburgh
Responsible party
Alison Morris (Professor, University of Pittsburgh) — Principal investigator
First posted
Dec 26, 2018
Start date
Dec 2022 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Jul 7, 2022

Study contacts

Alison Morris, MD, MS
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion